Suppr超能文献

Editorial: New strategies for treating fusion-driven sarcomas.

作者信息

Espinosa-Cotton Madelyn, Lee Sean B, Patel Anand G

机构信息

Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY, United States.

Department of Pathology and Laboratory Medicine, Tulane University School of Medicine, New Orleans, LA, United States.

出版信息

Front Cell Dev Biol. 2025 Apr 3;13:1600133. doi: 10.3389/fcell.2025.1600133. eCollection 2025.

Abstract
摘要

相似文献

1
Editorial: New strategies for treating fusion-driven sarcomas.
Front Cell Dev Biol. 2025 Apr 3;13:1600133. doi: 10.3389/fcell.2025.1600133. eCollection 2025.
2
SS18-SSX and SSX c-terminus antibodies for identification of specific fusion oncoprotein in mesenchymal neoplasms.
Pathology. 2025 Aug;57(5):579-584. doi: 10.1016/j.pathol.2024.11.013. Epub 2025 Feb 12.
3
Combinatorial strategies to potentiate the efficacy of HDAC inhibitors in fusion-positive sarcomas.
Biochem Pharmacol. 2022 Apr;198:114944. doi: 10.1016/j.bcp.2022.114944. Epub 2022 Feb 7.
5
Detection of Novel Tyrosine Kinase Fusion Genes as Potential Therapeutic Targets in Bone and Soft Tissue Sarcomas Using DNA/RNA-based Clinical Sequencing.
Clin Orthop Relat Res. 2024 Mar 1;482(3):549-563. doi: 10.1097/CORR.0000000000002901. Epub 2023 Nov 28.
6
Biological and therapeutic insights from animal modeling of fusion-driven pediatric soft tissue sarcomas.
Dis Model Mech. 2024 Jun 1;17(6). doi: 10.1242/dmm.050704. Epub 2024 Jun 25.
7
Identification of a novel MTAP-RAF1 fusion in a soft tissue sarcoma.
Diagn Pathol. 2018 Oct 12;13(1):77. doi: 10.1186/s13000-018-0759-z.
8
p53 immunohistochemical analysis of fusion-positive uterine sarcomas.
Histopathology. 2021 May;78(6):805-813. doi: 10.1111/his.14292. Epub 2021 Feb 14.
9
MAD::NUT Fusion Sarcoma: A Sarcoma Class With NUTM1, NUTM2A, and NUTM2G Fusions and Possibly Distinctive Subtypes.
Mod Pathol. 2025 May;38(5):100729. doi: 10.1016/j.modpat.2025.100729. Epub 2025 Feb 6.

本文引用的文献

2
PAX3-FOXO1 dictates myogenic reprogramming and rhabdomyosarcoma identity in endothelial progenitors.
Nat Commun. 2023 Nov 15;14(1):7291. doi: 10.1038/s41467-023-43044-1.
3
VGLL2-NCOA2 leverages developmental programs for pediatric sarcomagenesis.
Cell Rep. 2023 Jan 31;42(1):112013. doi: 10.1016/j.celrep.2023.112013. Epub 2023 Jan 18.
4
Rhabdomyosarcoma.
Nat Rev Dis Primers. 2019 Jan 7;5(1):1. doi: 10.1038/s41572-018-0051-2.
7
Vincristine, irinotecan, and temozolomide in patients with relapsed and refractory Ewing sarcoma.
Pediatr Blood Cancer. 2013 Oct;60(10):1621-5. doi: 10.1002/pbc.24621. Epub 2013 Jun 15.
8
Irinotecan and temozolomide for Ewing sarcoma: the Memorial Sloan-Kettering experience.
Pediatr Blood Cancer. 2009 Dec;53(6):1029-34. doi: 10.1002/pbc.22206.
9
Fusion between CIC and DUX4 up-regulates PEA3 family genes in Ewing-like sarcomas with t(4;19)(q35;q13) translocation.
Hum Mol Genet. 2006 Jul 1;15(13):2125-37. doi: 10.1093/hmg/ddl136. Epub 2006 May 22.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验